Brief: Immunotech Biopharm Receives Notice Of Rejection For Conditional New Drug Application For EAL Dated 27 April 2026
28/04/2026 16:28
April 28 (Reuters) - Immunotech Biopharm Ltd 6978.HK: RECEIVES NOTICE OF REJECTION FOR CONDITIONAL NEW DRUG APPLICATION FOR EAL DATED 27 APRIL 2026 CDE STATES NEW DRUG APPLICATION FOR EAL CANNOT BE APPROVED WITHOUT CONFIRMATORY TRIAL RESULTS TO PREPARE CONFIRMATORY CLINICAL STUDY AND PLANS TO RESUBMIT EAL APPLICATION APPLIES FOR RESUMPTION OF TRADING EFFECTIVE 9:00 A.M. 29 APRIL 2026 Further company coverage: 6978.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunotech Biopharm
See all newsBrief: Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan
Brief: Immunotech Biopharm Receives Notice Of Rejection For Conditional New Drug Application For EAL Dated 27 April 2026
Brief: Trading In Shares Of Immunotech Biopharm Will Be Halted At 1:00 PM On April 28, HKEX Says
Brief: Immunotech Biopharm Posts Loss And Total Comprehensive Expense For Year Attributable Rmb230.8 Million
Brief: Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN